How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective. (Q52881909)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 2014

edit

Language	Label	Description	Also known as
English	How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective.	scientific article published in February 2014

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

editorial

0 references

title

How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

author

Irvin M. Modlin

series ordinal

3

object named as

Irvin M Modlin

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

author name string

Vikas Prasad

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

Winfried Brenner

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

publication date

1 February 2014

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

published in

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

volume

41

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

page(s)

202-204

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

cites work

A 5-decade analysis of 13,715 carcinoid tumors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Exosomes in tumor microenvironment influence cancer progression and metastasis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00259-013-2593-6

retrieved

21 January 2018

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/24196915

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/24196915

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/24196915

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00259-013-2593-6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

PubMed publication ID

24196915

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24196915

retrieved

9 May 2018

reference URL

http://europepmc.org/abstract/MED/24196915

ResearchGate publication ID

258335923

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52881909&oldid=2220956355"